A Study of the Long-Term Safety and Effectiveness of Adalimumab for Repeat Treatment of Pediatric Patients with Ulcerative Colitis


About this study

The purpose of this study is to assess the long-term safety and effectiveness of repeat treatment with adalimumab in pediatric patients who have ulcerative colitis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Must have successfully completed previous study M11-290 

Exclusion Criteria

  • Is considered by the investigator, for any reason, to be an unsuitable candidate

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

William Faubion, M.D.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions